Outcomes of Placebo-Controlled Trials of Pramlintide in Type 2 Diabetes
| Trial, Duration | Change in HbA1c Level, % | PValue | Change in PPG, mg/dL | PValue | Change in Weight, kg | PValue |
|---|---|---|---|---|---|---|
| HbA1c = glycated hemoglobin; bid = 2 times daily; NR = not reported; PPG = postprandial glucose; tid = 3 times daily. | ||||||
| aCompared with placebo. | ||||||
| bCompared with placebo for both dosages combined. | ||||||
| Riddle et al, 2007,9 16 wk | ||||||
| Pramlintide, 60 or 120 μg bid-tid | −0.70 | <.05a | −24.4 | <.001a | −1.6 | <.001a |
| Placebo | −0.36 | −0.4 | +0.7 | |||
| Ratner et al, 2002,8 52 wk | ||||||
| Pramlintide, 75 μg tid | −0.50 | >.05a | NR | −0.5 | <.001a | |
| Pramlintide, 150 μg tid | −0.60 | <.001a | NR | −1.4 | <.001a | |
| Placebo | −0.20 | NR | +1.0 | |||
| Hollander et al, 2003,6 52 wk | ||||||
| Pramlintide, 90 μg bid | −0.35 | NR | −0.5 | |||
| Pramlintide, 120 μg bid | −0.62 | <.001b | NR | −1.25 | <.003b | |
| Placebo | −0.22 | NR | +0.6 | |||